

TREAT Asia

HIV Observational Database

(TAHOD)

Background

Therapeutics Research • Education • AIDS Training

TREATASIA

- A cooperative network of clinicians throughout Asia and the Pacific that aims to expand capacity for the broader introduction of HIV/AIDS treatments in the region



- A multi-centre, observational study of patients with HIV
- Aims to assess HIV disease natural history in treated and untreated patients in the Asia and Pacific region.

Therapeutics Research • Education • AIDS Training

TREATASIA



March 2006

Site selection

- A number of sites were involved with TREAT Asia
- Devised a site survey
 - Distributed to all sites
 - Gauged interest and ability to comply with TAHOD study methods
 - Electronic data transfer - email
 - Initial 3 year commitment
 - Local ethics approval
- Aimed for broad representation across the region
- Initially 11 participating sites in the Asia and Pacific region
 - 13 from September 2004
 - 15 from September 2005

Patient selection

- Patient recruitment
 - Can't hope to recruit patients that are entirely representative
 - Not a surveillance mechanism
 - Scientifically better to get good, consistent data on a limited number of patients that can be reliably followed-up
- Target of 200 patients per site
- Consecutive series of regularly attending patients
- Stratified by antiretroviral treatment
 - Balances random sampling with need for good follow-up
- Gives good data on HIV disease natural history

TAHOD

- TAHOD population
 - Male 71%
 - Non-pediatrics, patients 18 years or older
 - Urban patients
 - Centers for excellence
 - Public funded population
- Toxicity data are collected for research purposes
- Data are collected electronically in Microsoft Excel format
 - Transferred to NCHECR
 - Compressed in Winzip format

Patient demographics

Male		71%
Age (years) mean (SD)		36 (9.9)
range		18- 90 years
Exposure:	MSM	18%
	IDU	4%
	Hetero	64%
	Other/NK	14%
CD4 (cells/mm³) mean (SD)		307 (229)
HIV (copies/ml) median (IQR)		400 (400–8,900)
Prior AIDS		41%
ARVs:	HAART	77%
	Mono/double	2%
	None	21%

Toxicity data collection

- **Data specification version 1**
 - **Reason for treatment cessation**
 - **Laboratory tests**
 - **Haemoglobin, ALT**
- **Data specification version 2 (beginning March 2006)**
 - **Grade 3-4 clinical adverse events**
 - **AACTG criteria**
 - **Additional laboratory tests**
 - **When collected according to local site practice**

Adverse events

- **CARDIAC**
- **CLINICAL HEPATITIS**
- **DEPRESSION/ANXIETY**
- **DIABETES**
- **DIARRHOEA**
- **FAT ACCUMULATION**
- **FATIGUE**
- **FRACTURE**
- **IMMUNE RECONSTITUTION SYNDROME (IRS)**
- **LACTIC ACIDOSIS (DEFINITIVE & PRESUMPTIVE)**
- **LIPOATROPHY**
- **NAUSEA/VOMITING**
- **PANCREATITIS**
- **PERIPHERAL NEUROPATHY**
- **RASH**
- **RENAL STONE**
- **STROKE**
- **OTHERS**
- **UNKNOWN**

Laboratory tests

- **Blood pressure**
(systolic and diastolic)
- **Haemoglobin**
- **Cholesterol, fasting**
- **HDL, fasting**
- **Glucose, fasting**
- **Triglycerides, fasting**
- **Blood amylase,**
- **Blood creatinine**
- **Lactate**
- **Lipase**
- **Alkaline phosphatase**
- **ALT**
- **SGPT, SGOT**
- **Bilirubin**

Toxicity data collection

- **Toxicity data are to be collected prospectively for research purposes**
- **Data are collected in Microsoft excel format and transferred to NCHECR for central aggregation and analysis**
 - **Every 6 months**
- **TAHOD Steering Committee fully support the collaboration of research into long-term monitoring of treatment related adverse events in the resource limited settings**